182 related articles for article (PubMed ID: 35311521)
1. Proximal Binding Pocket Arg717 Substitutions in Escherichia coli AcrB Cause Clinically Relevant Divergencies in Resistance Profiles.
Zwama M; Nishino K
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239221. PubMed ID: 35311521
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics Reveal Potential Natural Substrates of AcrB in Escherichia coli and Salmonella enterica Serovar Typhimurium.
Wang-Kan X; Rodríguez-Blanco G; Southam AD; Winder CL; Dunn WB; Ivens A; Piddock LJV
mBio; 2021 Mar; 12(2):. PubMed ID: 33785633
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
Mowla R; Wang Y; Ma S; Venter H
Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
[TBL] [Abstract][Full Text] [Related]
4. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
[TBL] [Abstract][Full Text] [Related]
5. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
[TBL] [Abstract][Full Text] [Related]
6. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.
Blair JM; Bavro VN; Ricci V; Modi N; Cacciotto P; Kleinekathӧfer U; Ruggerone P; Vargiu AV; Baylay AJ; Smith HE; Brandon Y; Galloway D; Piddock LJ
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3511-6. PubMed ID: 25737552
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance.
Swick MC; Morgan-Linnell SK; Carlson KM; Zechiedrich L
Antimicrob Agents Chemother; 2011 Feb; 55(2):921-4. PubMed ID: 21098250
[TBL] [Abstract][Full Text] [Related]
8. Boosting the Antibacterial Activity of Azithromycin on Multidrug-Resistant
Al-Marzooq F; Ghazawi A; Daoud L; Tariq S
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240007
[TBL] [Abstract][Full Text] [Related]
9. Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB.
Bohnert JA; Schuster S; Seeger MA; Fähnrich E; Pos KM; Kern WV
J Bacteriol; 2008 Dec; 190(24):8225-9. PubMed ID: 18849422
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
[TBL] [Abstract][Full Text] [Related]
11. Resistance in Escherichia coli: variable contribution of efflux pumps with respect to different fluoroquinolones.
Huguet A; Pensec J; Soumet C
J Appl Microbiol; 2013 May; 114(5):1294-9. PubMed ID: 23414263
[TBL] [Abstract][Full Text] [Related]
12. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
[TBL] [Abstract][Full Text] [Related]
13. New Topoisomerase Inhibitors: Evaluating the Potency of Gepotidacin and Zoliflodacin in Fluoroquinolone-Resistant Escherichia coli upon
Schuster S; Vavra M; Köser R; Rossen JWA; Kern WV
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199388
[TBL] [Abstract][Full Text] [Related]
14. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Bohnert JA; Schuster S; Fähnrich E; Trittler R; Kern WV
J Antimicrob Chemother; 2007 Jun; 59(6):1216-22. PubMed ID: 17062614
[TBL] [Abstract][Full Text] [Related]
15. Perturbed structural dynamics underlie inhibition and altered efflux of the multidrug resistance pump AcrB.
Reading E; Ahdash Z; Fais C; Ricci V; Wang-Kan X; Grimsey E; Stone J; Malloci G; Lau AM; Findlay H; Konijnenberg A; Booth PJ; Ruggerone P; Vargiu AV; Piddock LJV; Politis A
Nat Commun; 2020 Nov; 11(1):5565. PubMed ID: 33149158
[TBL] [Abstract][Full Text] [Related]
16. Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB.
Schuster S; Vavra M; Kern WV
Antimicrob Agents Chemother; 2016 Jul; 60(7):4315-23. PubMed ID: 27161641
[TBL] [Abstract][Full Text] [Related]
17. The induced and intrinsic resistance of
Dai J-S; Xu J; Shen H-J; Chen N-P; Zhu B-Q; Xue Z-J; Chen H-H; Ding Z-S; Ding R; Qian C-D
Microbiol Spectr; 2024 Jan; 12(1):e0323723. PubMed ID: 38038452
[TBL] [Abstract][Full Text] [Related]
18. β-Lactam selectivity of multidrug transporters AcrB and AcrD resides in the proximal binding pocket.
Kobayashi N; Tamura N; van Veen HW; Yamaguchi A; Murakami S
J Biol Chem; 2014 Apr; 289(15):10680-10690. PubMed ID: 24558035
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance.
Hooda Y; Sajib MSI; Rahman H; Luby SP; Bondy-Denomy J; Santosham M; Andrews JR; Saha SK; Saha S
PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007868. PubMed ID: 31730615
[TBL] [Abstract][Full Text] [Related]
20. Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.
Sato T; Suzuki Y; Shiraishi T; Honda H; Shinagawa M; Yamamoto S; Ogasawara N; Takahashi H; Takahashi S; Tamura Y; Yokota SI
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
